Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Clinical trial NCT07524634 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07524634
- Sponsor
- Case Comprehensive Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2031-06-01
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.